文献速递类风湿关节炎

疾病活动度指导的TNF抑制剂剂量优化包括停药在类风湿关节炎中有效长达10年:DRESS研究的观察性随访

Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究为DRESS研究随机阶段后允许所有患者进行疾病活动度指导剂量优化的观察性长期扩展研究,共纳入170例患者,127例完成10年随访。10年间平均DAS28-CRP保持低位(2.13,95%CI 2.10-2.16),b/tsDMARD剂量从基线97%(95%CI 96-99%,n=170)降至第10年56%(95%CI 49-63%,n=127)。161例尝试优化者中119例(74%)达到停药,25例(21%,95%CI 14-29%)从未需重启b/tsDMARD;结论认为包括停药和多次减量尝试的长期剂量优化安全有效。

要点

  • 10年间平均DAS28-CRP为2.13(95%CI 2.10-2.16),疾病活动度保持低位。
  • b/tsDMARD剂量从基线97%(95%CI 96-99%,n=170)降至第10年56%(95%CI 49-63%,n=127)。
  • 161例尝试优化者中119例(74%)达到停药,25例(21%,95%CI 14-29%)从未重启b/tsDMARD。

核心结论

  • 长期疾病活动度指导的TNF抑制剂剂量优化(包括停药和多次减量尝试)在RA中保持安全有效。

研究设计与样本

  • DRESS研究随机阶段(0-18个月)后允许所有患者进行疾病活动度指导剂量优化的观察性长期扩展研究,纳入完成3年扩展期的患者,共170例,127例完成10年随访。

主要发现

  • 10年间平均时间加权DAS28-CRP为2.13(95%CI 2.10-2.16)。
  • b/tsDMARD年使用量占每日限定剂量的比例从基线97%(95%CI 96-99%,n=170)降至第10年56%(95%CI 49-63%,n=127)。
  • 161例尝试优化者中119例(74%)达到停药,停药中位持续时间7个月(四分位距3-33个月),25例(21%,95%CI 14-29%)从未需重启b/tsDMARD。
  • 首次优化尝试后平均剂量降低48%(n=159),后续尝试平均降低33%(n=86)。
  • 86例中有41例(48%)放射学进展超过最小可检测变化(5.7单位),进展与疾病活动度相关,而非b/tsDMARD使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to investigate the safety and effectiveness of disease activity-guided dose optimization of TNF inhibitors in RA over 10 years. METHODS: The study involved an observational long-term extension of a randomized study of participants who completed the 3-year extension of the DRESS-study. After the randomized phase (months 0-18), disease activity-guided dose optimization was allowed for all. The main outcomes were mean time-weighted DAS28-CRP; biologic and targeted synthetic DMARD (b/tsDMARD) use per year, as proportion of daily defined dose; proportion of patients reaching discontinuation; durability and effectiveness of subsequent dose reduction attempts; and radiographic progression between years 3 and 10 using the Sharp-van der Heijde score. RESULTS: A total of 170 patients were included, of whom 127 completed the 10-year follow-up. The mean disease activity remained low (DAS28-CRP 2.13, 95% CI 2.10-2.16), while the b/tsDMARD dose reduced from 97% at baseline (95% CI 96-99%, n = 170) to 56% at year 10 (95% CI 49-63%, n = 127). Of 161 participants with an optimization attempt, 119 (74%) reached discontinuation with a median duration of 7 months (interquartile range 3-33 months), and 25 participants never had to restart their b/tsDMARD (21%, 95% CI 14-29%). The mean dose reduction after dose optimization was 48% (n = 159) for the first optimization attempt, and 33% for a subsequent attempt (n = 86). Of the 86 participants, 41 (48%) had radiographic progression exceeding the smallest detectable change (5.7 units), and progression was associated with disease activity, not b/tsDMARD use. CONCLUSION: Long-term disease activity-guided dose optimization of TNF inhibitors in RA, including discontinuation and multiple tapering attempts, remains safe and effective.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. van der Togt CJT, den Broeder N, Boonstra MS, et al. Disease activity-guided dose optimization including discontinuation of TNF inhibitors in rheumatoid arthritis is effective for up to 10 years: an observational follow-up of the DRESS study. Rheumatology (Oxford). 2025. PMID: 38346712. doi:10.1093/rheumatology/keae103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。